-+ 0.00%
-+ 0.00%
-+ 0.00%

CREATIVE MEDICAL TECHNOLOGY HOLDINGS SUCCESSFULLY COMPLETES ENROLLMENT AND TREATMENT ACROSS ENTIRE FDA-CLEARED ADAPT TRIAL, INCLUDING OPIOID COHORT, ADVANCING CELZ-201 / OLASTROCEL TOWARD RMAT EVALUATION AND PHASE 3 PLANNING

路透·08/20/2026 13:15:00

登录查看新闻详情